Height and mortality after myocardial infarction

Area of Science:

• Cardiology
• Epidemiology
• Human Physiology

Background:

• The Beta Blocker Heart Attack Trial (BHAT) provided a unique dataset for retrospective analysis.
• Investigating non-traditional risk factors for cardiovascular disease mortality is crucial.

Purpose of the Study:

• To examine the association between patient height and mortality within the BHAT cohort.
• To determine if sex influences the relationship between height and mortality.

Main Methods:

• A case-control analysis was performed on data from the completed Beta Blocker Heart Attack Trial (BHAT).
• Relative risk (RR) was calculated for height reduction, controlling for relevant covariates.
• Subgroup analyses were conducted based on sex and treatment allocation (propranolol).

Main Results:

• A 4-inch reduction in height was associated with a relative risk (RR) of 1.18 for mortality (95% CI, 0.92 to 1.51).
• The association between short stature and mortality was significant in males (RR 1.26, 95% CI 0.96 to 1.63) but not in females (RR 0.89, 95% CI 0.49 to 1.59).
• In untreated males, the RR for mortality per 4-inch height reduction was 1.41 (95% CI 1.00 to 1.99).

Conclusions:

• Short stature may serve as a marker for increased coronary heart disease mortality risk in men.
• Childhood factors predisposing males to mortality from coronary heart disease later in life are hypothesized.
• Further research is needed to elucidate the underlying mechanisms linking short stature to cardiovascular mortality.